Loading… Բեռնվում է…

The agency reports no evidence of ongoing transmission, but the unconfirmed diagnosis prevents it from judging whether Russia’s seven-day contact monitoring was sufficient.
The World Health Organization (WHO) reports no evidence of ongoing transmission following a laboratory worker’s death in Russia, but says the unconfirmed diagnosis prevents it from independently assessing the risk or whether Russia’s precautions were adequate. Its outbreak report, described by Ars Technica on 12 October, also leaves open the possibility of exposure linked to the laboratory. The absence of detected spread does not establish what caused the fatal illness.
The response followed the death on 2 October of Darya Shipilova, 28, who worked at the Irkutsk Anti-Plague Research Institute in Shelekhov, Siberia. Early media reports put the onset of her illness on 29 September. Russian authorities described severe pneumonia of unknown cause, denied a connection with the institute and said there was no danger of a plague outbreak and the region’s public-health situation was stable. The Guardian reported on 7 October that laboratory staff had been confined for three days during testing and nearby hospitals faced restrictions. Ars Technica reported on 5 October that roughly 200 people were under medical observation, several hospitals were quarantined and dozens of people were in isolation.
Russian authorities told WHO that contact monitoring had ended by 9 October, after a seven-day monitoring period for all contacts. They said no high-threat pathogens studied at the laboratory had been detected in those contacts. WHO said that without a confirmed cause of the fatal illness, it could not independently assess whether seven days was sufficient to exclude all plausible causes.

Russia’s designated contact point for international health reporting said authorities conducted 5,500 laboratory tests on contacts. The tests covered influenza, SARS-CoV-2—the virus that causes COVID-19—other respiratory infections and bacterial infections, including plague and Streptococcus. Authorities reported the following findings, as well as a few opportunistic infections, which can occur when the body’s defences are weakened:
| Infection | Reported cases |
|---|---|
| COVID-19 | 2 |
| Rhinovirus | 3 |
| Haemophilus bacteria, a group that includes causes of respiratory infections and pneumonia | 1 |
Russian authorities also said Shipilova was not infected with Yersinia pestis, the bacterium that causes plague, and had been vaccinated against it because of her occupational risk. They denied any failure of laboratory safety or security at the institute and said she had not travelled outside the region in the two weeks before becoming ill. WHO nevertheless said uncertainty about the diagnosis, the source of exposure and how exposure occurred limited confidence in its assessment; it did not rule out laboratory-associated exposure.
Irkutsk Governor Igor Kobzev said on 8 October that preventive measures had been completed, Fox News reported on 11 October, citing the Associated Press. Nature reported on 8 October that Russian officials had disclosed Shipilova’s plague vaccination on 7 October, five days after her death, and said thousands of tests had found no dangerous pathogens in her or others who might have been exposed. The subsequent account to WHO supplied the 5,500-test total and named several infections found among contacts, but did not establish the cause of her death.
Russia disputes concerns about its disclosures. Nature reported that Kremlin officials told CNN Russia had kept WHO informed “in accordance with established practice”. WHO’s outbreak report says it learned of the death through media reports on 2 October and requested information from Russia on 3, 6, 7 and 8 October. Russia’s designated contact point first responded on 6 October, saying no plague case had been recorded in Irkutsk Oblast and that the worker had developed symptoms compatible with an acute respiratory viral infection before dying of severe pneumonia of undetermined cause.
On 6 October, WHO spokesperson Christian Lindmeier said there was no sign of a wider outbreak. All contacts had reportedly been identified and were being monitored, with none showing symptoms as of that date, he said. Russian officials were still investigating whether pneumonic plague caused the death. These regional risk estimates preceded WHO director general Tedros Adhanom Ghebreyesus’s statement on 7 October that the agency lacked the full picture and could not conduct a full risk assessment:
| Area | Risk estimate |
|---|---|
| Irkutsk | Moderate to low |
| Rest of Russia | Low |
| Europe | Very low |
Tedros called on 7 October for timely, complete and transparent information to clarify conflicting reports and assess public risks. WHO had also asked Russia about unconfirmed media reports of a second employee with pneumonia of undetermined cause and was awaiting an answer as of that date. That reported illness was not a confirmed second plague case. Maria Van Kerkhove, WHO’s director of epidemic and pandemic management, said the agency did not know what caused Shipilova’s illness or how she became infected.
The US Centers for Disease Control and Prevention (CDC) was coordinating with other federal agencies to identify and monitor travelers arriving from Siberia, director Erica Schwartz said at a Wall Street Journal health forum on 7 October. She assessed the threat to the United States as “extremely low”, Fox News reported on 11 October.
Schwartz said the CDC was working with the departments of Homeland Security, State and War, among other federal agencies, to track potential arrivals. A port health station at New York’s John F. Kennedy International Airport could monitor and screen travelers from the area if they entered the United States. She also said US officials were discussing with Moscow what had happened and were working with information about an unconfirmed pneumonic-plague case. The screening response did not establish that the death was caused by plague.
In comments published by the Science Media Centre on 5 October, Dr Zania Stamataki, an associate professor of viral immunology at the University of Birmingham, said Yersinia pestis had not been confirmed as the cause. Dr Simon Clarke, an associate professor in cellular microbiology at the University of Reading, said more details were needed to distinguish an isolated case, exposure at work or wider transmission. Ars Technica’s 5 October report also described accounts of a laboratory accident as unconfirmed.
Fortune’s 5 October newsletter, citing Axios, carried an unconfirmed account of a worker breaking a tube containing a pneumonic-plague pathogen on 25 September and dying in hospital during the night of 1–2 October. Clarke said a broken tube would not automatically lead to exposure or infection. The death does not establish that plague bacteria escaped from the laboratory.
Pneumonic plague means plague infection has reached the lungs. Unlike bubonic plague, which enters the body through infected flea bites, the pneumonic form can spread between people through respiratory droplets during close contact, Clarke explained. The European Centre for Disease Prevention and Control (ECDC) says transmission generally requires close and prolonged contact with someone already showing symptoms.
Symptoms can include fever, chest pain, coughing and rapidly developing pneumonia, according to the CDC. Pneumonic plague is nearly always fatal without prompt treatment, Clarke said. Antibiotics work well when given early enough and are often given preventively after exposure. Rapid diagnosis and identifying contacts allow treatment before the illness progresses. Schwartz said common antibiotics available to US physicians can treat the disease; ECDC says effective antibiotics are readily available in the European Union, where no plague case has occurred for decades.
In the 5 October expert reaction, Stamataki said plague persists in rodent populations across Africa, Asia and the Americas, with human cases every year. Laboratories study live bacteria to develop diagnostic tests and vaccines and monitor antibiotic resistance. Clarke said the purpose of the work at the Irkutsk laboratory remained unclear.
Clarke described high-containment laboratories as combining trained staff, strict procedures, safety cabinets and airflow systems. Laboratory-acquired infections are rare, though possible. Stamataki outlined UK requirements for handling live Yersinia pestis at Containment Level 3, a high-containment laboratory standard. These are UK rules, not verified conditions at the Russian facility:
ECDC says patients with suspected or confirmed pneumonic plague should be isolated and offered appropriate treatment as assessed by a specialist healthcare provider. Close contacts should be rapidly identified and monitored. This guidance does not establish that Shipilova had plague or that a laboratory release occurred.
Ars Technica reported on 5 October that Kyrgyzstan was introducing quarantine controls at state border crossings and ECDC was monitoring the situation “very closely”. Those responses did not establish plague or wider transmission. Stamataki called for a full account and said early notification allows effective treatment and outbreak containment. Clarke identified transparency, rapid diagnosis and effective contact tracing as key measures for managing a plague outbreak.
WHO’s latest report leaves the cause of the fatal illness unresolved, preventing an independent judgment on whether the completed contact monitoring was sufficient. ECDC said on 6 October that it would continue monitoring the event and was proactively in contact with WHO Europe to discuss the situation.
A Tohoku University experiment found gains on later days in an eye-movement task. Rhythmic changes in brain blood volume were associated with better learning, but have not been shown to cause it.
2 min

Seeing a clinician, receiving medication and staying on it are different steps. A study of nearly 230,000 diagnosed young people found gaps across those stages.
4 min

Lab experiments link iron-ion exposure to DNA damage in nearby cells. Mouse tumors and astronaut molecular changes offer different kinds of evidence.
3 min